Guardian Pharmacy Services, Inc.
NYSE:GRDNMedical - Distribution
+$0.17 today
- Market cap
- $3.09B
- Beta
- 0.08
- P/E (TTM)
- 52.0
- EPS (TTM)
- $0.84
Volume 0.45M
Average 0.48M
GRDN EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Guardian Pharmacy Services, Inc.NYSE: GRDN
EPS (Diluted) · Q2 FY2026 · quarter ended Jun 2026
EPS (Diluted) grows, but more slowly than its trailing trend
Q2 FY2026 EPS (Diluted) of $0.34 rose 142.9% year over year, behind the +168.2% change in trailing-twelve-month EPS (Diluted). Sequentially, it rose 61.9% from the prior quarter. Over 3 fiscal years it compounded at +10.4% a year.
Context
- EPS (Diluted) increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 5 analysts of $1.36 (+74.9%) for the fiscal year ending Dec 2026, a slowdown from the +144.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $0.34+61.9% QoQ
- Last fiscal yearDec 2025
- $0.78+144.1% YoY
- LTMJun 2026
- $1.03+168.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +142.9% | +109.7% | -33.1 pp |
| 1 year | +144.1% | +74.9% | -69.2 pp |
| 3-year CAGR | +10.4% | +29.0% | +18.6 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- 0.78 USD
- Year-over-year change
- +144.1%
- 4-year CAGR
- +30.4%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0.78 | +144.1% |
| FY2024 | 2024-12-31 | (1.77) | -553.8% |
| FY2023 | 2023-12-31 | 0.39 | -32.8% |
| FY2022 | 2022-12-31 | 0.58 | +114.8% |
| FY2021 | 2021-12-31 | 0.27 | — |
EPS (Diluted) vs competitors
How GRDN compares with its peers on the latest reported figures
- GRDN's LTM Jun 2026 EPS (Diluted) of $1.03 is the 4th highest of the 11 companies compared; the peer median is -$0.48.
- Its year-over-year change of +168.2% is the 2nd highest of 11, against a peer median of +4.8%.
- Over three fiscal years its annual growth of +10.4% compares with a peer median of +54.6%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | $8.19 | +618.4% | — | |
| LTM Sep 2026 | $7.24 | +11.7% | +74.2% | |
| LTM Sep 2026 | $1.84 | -2.1% | +34.9% | |
GRDNGuardian Pharmacy Services, Inc. | LTM Jun 2026 | $1.03 | +168.2% | +10.4% |
| LTM Jun 2026 | -$0.43 | +48.3% | — | |
| LTM Jun 2026 | -$0.44 | +30.8% | — | |
| LTM Sep 2026 | -$0.52 | +16.1% | — | |
| LTM Mar 2026 | -$1.82 | -7.1% | — | |
| LTM Mar 2026 | -$1.84 | -35.3% | — | |
| LTM Sep 2026 | -$2.08 | -58.8% | — | |
| LTM Mar 2026 | -$17.85 | -259.2% | — | |
| Peer median (excluding GRDN) | -$0.48 | +4.8% | +54.6% | |
Competitors are the stored peer set for GRDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 792.07M | 908.91M | 1.05B | 1.23B | 1.45B |
| Cost of Revenue | 630.81M | 723.04M | 837.88M | 984.04M | 1.17B |
| Gross Profit | 161.27M | 185.87M | 208.31M | 244.37M | 282.04M |
| Gross Margin | 20.4% | 20.4% | 19.9% | 19.9% | 19.5% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 131.12M | 133.88M | 167.36M | 307.29M | 193.13M |
| Operating Expenses | 131.12M | 133.88M | 167.36M | 307.29M | 193.13M |
| Depreciation & Amortization | 16.53M | 16.56M | 18.23M | 19.77M | 22.34M |
| EBITDA | 46.49M | 68.15M | 58.81M | (43.43M) | 96.42M |
| EBITDA Margin | 5.9% | 7.5% | 5.6% | -3.5% | 6.7% |
| Operating Income | 30.15M | 51.99M | 40.95M | (62.92M) | 88.91M |
| Operating Margin | 3.8% | 5.7% | 3.9% | -5.1% | 6.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.64M | 1.93M | 2.86M | 3.28M | 665K |
| Other Income / Expenses | (1.82M) | (2.33M) | (3.23M) | (3.56M) | (15.49M) |
| Income Before Tax | 28.33M | 49.66M | 37.72M | (66.48M) | 73.42M |
| Pre-Tax Margin | 3.6% | 5.5% | 3.6% | -5.4% | 5.1% |
| Income Tax Expense | 0 | 0 | 0 | 4.56M | 24.47M |
| Net Income | 16.31M | 35.42M | 23.9M | (87.29M) | 49.22M |
| Net Margin | 2.1% | 3.9% | 2.3% | -7.1% | 3.4% |
| EPS (Basic) | 0.27 | 0.58 | 0.39 | (1.77) | 0.79 |
| EPS (Diluted) | 0.27 | 0.58 | 0.39 | (1.77) | 0.78 |
| Weighted Avg Shares | 60.84M | 60.84M | 60.84M | 62.01M | 62.39M |
| Weighted Avg Shares (Diluted) | 60.84M | 60.84M | 60.84M | 62.01M | 63.3M |
Guardian Pharmacy Services, Inc.
NYSE:GRDN
Intrinsic Alpha fair value
Locked
Current Price
$48.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.